Best medication for type 2 diabetes, honestly
Type 2 diabetes treatment changed genuinely in the last decade — but not in the way the headlines suggest. Metformin remains the usual starting drug, while GLP-1s and SGLT2 inhibitors earned their place by protecting the heart and kidneys, not merely by lowering sugar. Below is each option, who it actually fits, and our recall-safety rating.
What the GLP-1 headlines leave out
Metformin is still the first-line drug for most people with type 2 diabetes: decades of evidence, very low cost, no weight gain, and no risk of hypoglycaemia on its own. GLP-1s (Ozempic, Trulicity, Mounjaro) and SGLT2 inhibitors (Jardiance, Farxiga) are added — often on top of metformin — and are chosen ahead of other options when someone also has heart disease, heart failure or chronic kidney disease, because they reduce those outcomes independently of blood sugar. The real barriers are cost and coverage, not effectiveness.
Metformin (Glucophage)
Biguanide
The standard first drug: effective, inexpensive, does not cause weight gain, and does not cause low blood sugar by itself. Start-up stomach upset is common and usually settles — limited by starting low, going slow and taking it with food. Long-term use can lower vitamin B12, so levels are checked periodically. It carries an FDA BOXED WARNING for lactic acidosis: it is contraindicated below an eGFR of 30, not started between 30 and 45, and is temporarily held around iodinated-contrast imaging and during dehydrating illness.
Semaglutide (Ozempic)
GLP-1 receptor agonist
A once-weekly injection that lowers blood sugar and typically produces meaningful weight loss, with proven cardiovascular benefit in people with established heart disease. Nausea is the main early effect. Like all GLP-1s it carries an FDA BOXED WARNING for thyroid C-cell tumours seen in rodents, and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Note: Ozempic is approved for type 2 diabetes — the same molecule for weight management is Wegovy.
Empagliflozin (Jardiance)
SGLT2 inhibitor
A daily tablet that makes the kidneys excrete glucose. Its standout value is outcome protection — reduced heart-failure hospitalisation and slowed kidney disease progression — It is CONTRAINDICATED in patients on dialysis, and is not recommended for blood-sugar control below an eGFR of 30, though its kidney-protection use extends lower. That protection is why it is often chosen when those conditions are present. Raises genital yeast/urinary infection risk. Sick-day rule: it is held during acute illness, prolonged fasting or a very-low-carbohydrate period, and stopped several days before major surgery, because those states are what precipitate ketoacidosis.
Glipizide
Sulfonylurea
An old, very cheap and effective sugar-lowering pill — but it works by pushing insulin out, so unlike the newer options it CAN cause hypoglycaemia and some weight gain. Still useful where cost is the binding constraint. It is contraindicated in type 1 diabetes and diabetic ketoacidosis. In older, frail or malnourished people and in kidney or liver impairment the label calls for conservative dosing, because low blood sugar there can be prolonged rather than brief. The label also carries a special warning on cardiovascular mortality from the UGDP trial, and sulfonylureas can trigger haemolytic anaemia in G6PD deficiency.
Tirzepatide (Mounjaro)
GIP/GLP-1 agonist
A once-weekly injection acting on two gut hormones; among the most effective options for both blood sugar and weight — in the head-to-head SURPASS-2 trial it outperformed semaglutide 1 mg, which is narrower than a blanket claim of being best overall. Approved for type 2 diabetes; the same molecule for weight management is Zepbound. Carries the same BOXED WARNING as the GLP-1s (thyroid C-cell tumours; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2). Cost and coverage are often the deciding factor.
Dulaglutide (Trulicity)
GLP-1 receptor agonist
Another once-weekly GLP-1 injection with demonstrated cardiovascular benefit; a straightforward pen. Similar gastrointestinal side effects to the other GLP-1s, and the same class BOXED WARNING for thyroid C-cell tumours (contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2).
Dapagliflozin (Farxiga)
SGLT2 inhibitor
The other widely used SGLT2 inhibitor, with similar heart-failure and kidney benefits. Its own label is firmer than Jardiance's on one point: withhold it for at least 3 days before surgery or a procedure involving prolonged fasting. It is not recommended for blood-sugar control below an eGFR of 45. Same genital and urinary infection risk, and the same sick-day rule — stop it if you cannot eat or drink normally.
Sitagliptin (Januvia)
DPP-4 inhibitor
A well-tolerated daily tablet that is weight-neutral and rarely causes low blood sugar, but lowers blood sugar more modestly and has not shown the heart or kidney benefits of GLP-1s and SGLT2s. Its dose is reduced by kidney function — 50 mg if eGFR is 30 to 45, and 25 mg below 30 including on dialysis — so it is not off-limits like metformin, but it is not a flat 100 mg either. The label also warns about acute pancreatitis (stop and call), a heart-failure caution for the DPP-4 class, severe disabling joint pain, and bullous pemphigoid (a blistering rash needing hospital care). A reasonable choice when tolerability is the priority.
How to choose
The honest way to narrow it down — matched to your situation, not a ranking. These are common scenarios, not a complete rulebook; the final choice is a prescriber’s.
- Newly diagnosed, no complicating conditions
- Metformin — first-line, cheap, well-proven, alongside diet and activity changes.
- You also have heart disease, heart failure or chronic kidney disease
- An SGLT2 inhibitor (Jardiance, Farxiga) or a GLP-1 — these are chosen for organ protection, not just sugar.
- Weight loss is a major goal too
- A GLP-1 or tirzepatide, which produce the largest weight reduction of the diabetes drugs.
- Cost or insurance coverage is the binding constraint
- Metformin, and if more is needed a sulfonylurea like glipizide — both are inexpensive generics.
- Metformin's stomach upset is intolerable
- The extended-release form often helps; otherwise a DPP-4 inhibitor or another class — a prescriber's call, not a reason to stop treating.
Type 2 diabetes medications at a glance
| Medication | Class | Form | Weight effect | Notable benefit / caution |
|---|---|---|---|---|
| Metformin | Biguanide | Tablet | Neutral | First-line; GI upset early; B12 over years |
| Semaglutide (Ozempic) | GLP-1 | Weekly injection | Loss | CV benefit; nausea; cost. Tell any surgeon or anaesthetist — slowed stomach emptying has caused aspiration under anaesthesia despite normal fasting |
| Tirzepatide (Mounjaro) | GIP/GLP-1 | Weekly injection | Largest loss | Very effective; nausea; cost. Same anaesthesia warning as the GLP-1s, and it can make oral contraceptives fail — switch to a non-oral method or add a barrier |
| Dulaglutide (Trulicity) | GLP-1 | Weekly injection | Loss | CV benefit; nausea |
| Empagliflozin (Jardiance) | SGLT2 | Tablet | Slight loss | Heart-failure + kidney protection; yeast/UTI |
| Sitagliptin (Januvia) | DPP-4 | Tablet | Neutral | Well tolerated; modest lowering |
| Dapagliflozin (Farxiga) | SGLT2 inhibitor | Daily tablet | Modest loss | Heart-failure and kidney benefit; withhold at least 3 days before surgery; not recommended for glucose control below eGFR 45 |
| Glipizide | Sulfonylurea | Tablet | Gain | Cheap; CAN cause hypoglycaemia; contraindicated in type 1 diabetes and DKA |
What to expect
Type 2 diabetes is tracked by A1c — a blood test reflecting roughly the last three months — so treatment is judged on lab results, not on how you feel, and is usually reviewed about every three months until stable. Metformin starts lowering glucose within days but its full A1c effect takes weeks, and the dose is deliberately increased slowly to limit stomach upset. GLP-1s are also titrated up over weeks for the same reason. Treatment is layered rather than swapped: a second drug is commonly added to metformin rather than replacing it. Diet, activity and weight remain part of the plan at every stage, not an alternative to it.
When to get medical help
- Signs of very low blood sugar — shakiness, sweating, confusion, fast heartbeat — especially on a sulfonylurea or insulin, and more likely when another drug is added on top (doses often need reducing). Treat with fast sugar and tell your prescriber.
- On a GLP-1, tirzepatide or sitagliptin: severe, persistent abdominal pain, possibly radiating to the back and with vomiting — possible pancreatitis; stop the drug and seek care. Gallbladder problems (right-upper abdominal pain, fever, yellowing) are also a recognised class risk.
- A lump or swelling in the neck, trouble swallowing, hoarseness or persistent shortness of breath on a GLP-1 or tirzepatide — report promptly; these drugs carry a boxed warning about thyroid C-cell tumours.
- On an SGLT2 inhibitor: nausea, vomiting, abdominal pain, deep or laboured breathing, or unusual drowsiness — possible diabetic ketoacidosis, which can occur even with near-normal blood sugar. Seek urgent care.
- On an SGLT2 inhibitor: severe pain, swelling or redness in the genital or perineal area with fever — a rare but serious infection needing emergency care.
- On metformin: unusual muscle pain, trouble breathing, severe weakness or feeling very cold — rare lactic acidosis, more likely with significant kidney problems, dehydration or heavy alcohol use. Seek urgent care.
- New or worsening foot sores, numbness, or vision changes — complications that need prompt review rather than waiting for the next appointment.
- Severe unexplained joint pain, or new blistering of the skin, on sitagliptin — both are labeled reasons to stop and call.
- Tell any surgeon or anaesthetist you take a GLP-1 or tirzepatide — these slow stomach emptying, and stomach contents have entered the lungs under anaesthesia despite normal fasting. They are also not recommended in severe gastroparesis, and existing diabetic retinopathy needs monitoring.
Frequently asked questions
What is the best medication for type 2 diabetes?
For most people newly diagnosed it is still metformin — decades of evidence, very low cost, weight-neutral, and it does not cause low blood sugar on its own. If you also have heart disease, heart failure or chronic kidney disease, guidelines favour adding an SGLT2 inhibitor or a GLP-1 because those reduce those specific outcomes. The 'best' drug is therefore the one matched to your other conditions, not the newest one.
Is metformin still first-line, given GLP-1 drugs?
Yes for most people. GLP-1s are genuinely effective and have real cardiovascular benefits, but they are typically added to metformin rather than replacing it, and cost and coverage limit them for many. Where someone has established cardiovascular or kidney disease, a GLP-1 or SGLT2 may be started early or even first — but that is a targeted decision, not a wholesale replacement of metformin.
Ozempic vs Mounjaro vs Trulicity — what's the difference?
All three are once-weekly injections for type 2 diabetes. Trulicity (dulaglutide) and Ozempic (semaglutide) are GLP-1 receptor agonists; Mounjaro (tirzepatide) acts on two hormones (GIP and GLP-1) and produced the largest blood-sugar and weight reductions in trials. Ozempic and Trulicity have demonstrated cardiovascular benefit. In practice, coverage and tolerability often decide between them — a prescriber's call.
Do diabetes medications cause weight gain?
It depends on the class. Sulfonylureas (glipizide) and insulin tend to cause weight gain; metformin and DPP-4 inhibitors are roughly weight-neutral; SGLT2 inhibitors cause slight weight loss; and GLP-1s and tirzepatide cause the most weight loss. If weight matters to you, say so when the drug is chosen — the classes differ substantially.
Can type 2 diabetes be reversed without medication?
Substantial weight loss and sustained dietary change can bring blood sugar back into the normal range for some people — often described as remission rather than cure, because it can return. That is a real and worthwhile goal, usually pursued alongside medication rather than instead of it, and it should be done with clinical supervision, especially if you take drugs that can cause low blood sugar and may need reducing as you improve.
Why does metformin upset my stomach?
Gastrointestinal effects — nausea, loose stools, cramping — are the most common metformin side effect and usually appear early. They are typically managed by starting at a low dose, increasing slowly, taking it with food, and if needed switching to the extended-release form, which many people tolerate far better. It is worth working through with your prescriber rather than abandoning a first-line drug.
Guides for these medications
Sources
Treatment-role framing follows standard US clinical guidelines; each drug links to its FDA label and our rating. This is general reference information, not medical advice, and not a recommendation to take any drug — the choice is a decision to make with a clinician. If you are in crisis, call or text 988 (the US Suicide & Crisis Lifeline).